LBA51 Osimertinib treatment based on plasma T790M monitoring in patients with EGFR-mutant non-small cell lung cancer (NSCLC): EORTC Lung Cancer Group 1613 APPLE phase II randomized clinical trial.
Saved in:
| Title: | LBA51 Osimertinib treatment based on plasma T790M monitoring in patients with EGFR-mutant non-small cell lung cancer (NSCLC): EORTC Lung Cancer Group 1613 APPLE phase II randomized clinical trial. |
|---|---|
| Authors: | Masip, J. Remon1 (AUTHOR), Besse, B.1 (AUTHOR), Aix, S. Ponce2 (AUTHOR), Callejo, A.3 (AUTHOR), Al-Rabi, K.4 (AUTHOR), Caro, R. Bernabe5 (AUTHOR), Greillier, L.6 (AUTHOR), Tarruella, M. Majem7 (AUTHOR), Aransay, N. Reguart8 (AUTHOR), Monnet, I.9 (AUTHOR), Cousin, S.10 (AUTHOR), Lopez, P. Garrido11 (AUTHOR), Robinet, G.12 (AUTHOR), Campelo, M.R. Garcia13 (AUTHOR), Flandin, A-C. Madroszyk14 (AUTHOR), Mazieres, J.15 (AUTHOR), Pretzenbacher, Y.16 (AUTHOR), Fournier, B.17 (AUTHOR), Dingemans, A-M.C.18 (AUTHOR), Dziadziuszko, R.19 (AUTHOR) |
| Source: | Annals of Oncology. 2022 Supplement 7, Vol. 33, pS1419-S1419. 1p. |
| Database: | Academic Search Ultimate |
| ISSN: | 09237534 |
|---|---|
| DOI: | 10.1016/j.annonc.2022.08.053 |
